Navigation Links
Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Date:1/31/2008

$1,017,430 $855,415 $4,615,960 $4,196,706

Basic Earnings Per

Share(2) $0.76 $0.64 $3.44 $3.12

Average Number of Common

Shares Outstanding During

Each Period - Basic 1,338,559 1,346,087 1,342,552 1,345,386

Diluted Earnings Per

Share(2) $0.75 $0.63 $3.38 $3.08

Average Number of Common

Shares Outstanding During

Each Period - Diluted 1,367,895 1,379,180 1,374,342 1,374,053

See Notes to Results of Operations and Results of Operations -- As Adjusted.

Results of Operations -- As Adjusted

Wyeth has prepared the following presentation of its results of operations for the three months and full year ended December 31, 2007 and 2006, adjusted where noted below, to exclude productivity initiatives charges and the 2006 income tax adjustment, which are considered certain significant items during the 2007 and 2006 fourth quarter and full year.

The comparative results of operations -- as adjusted are as follows: (In thousands except per share amounts)

(UNAUDITED) -- AS ADJUSTED

Three Months Ended Full Year Ended

12/31/2007 12/31/2006 12/31/2007 12/31/2006

Net Revenue $5,763,526 $5,220,179 $22,399,798 $20,350,655

Cost of Goods Sold(3) 1,629,443 1,448,229 6,069,333 5,458,652

Selling, General and

Administrative

Expenses(3) 1,880,580 1,772,767 6,724,921 6,423,943

Research and Development

Expenses(3) 882,437 913,224 3,256,516 3,097,712

Interest Income, Net (17,071) (6,524) (90,511) (6,646)

Other Income, Net(1) (38,795) (65,951) (290,543) (271,490)

Income Before I
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... Boehringer Ingelheim today announced results from the RE-COVER(TM) ... direct thrombin inhibitor (DTI),(2) compared to dose-adjusted warfarin ... the trial were presented at the 51st American ... online in the New England Journal of ... primary outcome of the trial, six month incidence ...
(Date:12/4/2009)... Alberta Centre for Advanced Micro Nano Technology Products ... seminar, , EDMONTON, Dec. 4 /PRNewswire/ - Today ... how technologies like nanotechnology, biomaterials and microfluidics can ... innovative healthcare products that help promote health and ...
(Date:12/3/2009)... Houston, LLC announced today that it has updated ... vertical sleeve gastrectomy , along with the ... sleeve gastrectomy procedure at the facility was performed by ... October 20, 2009. The patient is reported as doing ...
(Date:12/3/2009)... FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: ... of compounds for the treatment of cardiovascular and metabolic ... patient visit in its Phase 2 FDG-PET clinical trial ... patients and was carried out at five sites in ...
Breaking Biology Technology:RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) a biopharmaceutical ... candidates for the treatment,of cancer and infectious diseases, ... officer, is scheduled to present at the 2007,Thomas ... at 1:30 p.m. Eastern Daylight Time. The conference ...
... - ... ... PDL BioPharma, Inc.,(PDL) (Nasdaq: PDLI ) today announced a ... of novel antibodies in,oncology and select immunological diseases, following a months-long,business ...
... Aug. 28 The American Chemical Society,(ACS) presented the ... prestigious 2007 Heroes of Chemistry award this week,at the ... new 100,percent renewable ingredient -- the first of its ... Tenn., by the DuPont Tate & Lyle Bio,Products joint ...
Other Biology Technology:ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference 2PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 2PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 3PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 4PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 5DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM) 2DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM) 3DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM) 4
(Date:12/3/2009)... A coating on windows or solar panels that repels ... next electric car? New Tel Aviv University research, just ... in assembling peptides at the nano-scale level that could ... few years. , Operating in the range of 100 ...
(Date:12/3/2009)... in warmer water, according to an intriguing new study suggesting ... Experiments with two species of young damselfish on Australia,s Great ... reef fish are either consistently timid, or consistently bold, and ... temperatures rise. , A slight lift of just one or ...
(Date:12/3/2009)... scientists from the U.S. Department of Energy,s (DOE) Brookhaven ... Science has made a major step in understanding how ... necessary to carry out important biological processes. The research, ... Nature Structural & Molecular Biology , confirms that many ...
Breaking Biology News(10 mins):A window that washes itself? 2Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Managed Health Services Partners With Milwaukee Health Services to Increase Access to Care for Underserved Communities 48218 1Managed Health Services Partners With Milwaukee Health Services to Increase Access to Care for Underserved Communities 48218 2Managed Health Services Partners With Milwaukee Health Services to Increase Access to Care for Underserved Communities 48218 3PHOENIX AHF Magic Johnson HIV Testing Caravan 26 Southwest Center for HIV AIDS to Host Free HIV Testing Event at Off Chute Too 48214 1PHOENIX AHF Magic Johnson HIV Testing Caravan 26 Southwest Center for HIV AIDS to Host Free HIV Testing Event at Off Chute Too 48214 2PHOENIX AHF Magic Johnson HIV Testing Caravan 26 Southwest Center for HIV AIDS to Host Free HIV Testing Event at Off Chute Too 48214 3PHOENIX AHF Magic Johnson HIV Testing Caravan 26 Southwest Center for HIV AIDS to Host Free HIV Testing Event at Off Chute Too 48214 4PHOENIX AHF Magic Johnson HIV Testing Caravan 26 Southwest Center for HIV AIDS to Host Free HIV Testing Event at Off Chute Too 48214 5PHOENIX AHF Magic Johnson HIV Testing Caravan 26 Southwest Center for HIV AIDS to Host Free HIV Testing Event at Off Chute Too 48214 6Caliper Life Sciences to Webcast Investor Session of Open House 12528 1Caliper Life Sciences to Webcast Investor Session of Open House 12528 2
... in his lab. Millions of people the world over ... that has yet provided a universally accepted solution. However, a ... has come up with a practical weight loss solution for ... , For this development, Yaniv Linde, a 32-year-old Ph.D. ...
... of the University of Pennsylvania have found that deleting a ... loss of stem cell reservoirs in adult mice. This gene, ... and mutations in proteins in the DNA damage response underlie ... work appears in the inaugural issue of Cell Stem Cell. ...
... N.Y. – Cold Spring Harbor Laboratory (CSHL) researchers led ... Hughes Medical Investigator (HHMI) Greg Hannon have identified a ... tumor suppressor network, called the p53 pathway, to fight ... on several fronts to understand the p53 pathway because ...
Other Biology News:How to lose weight and not go hungry: HU researcher develops drug that mimics feeling of 'fullness' 2Loss of stem cells correlates with premature aging in animal study 2Study shows big power of small RNAs, not just proteins, in halting cancer 2
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
XEDAR Antibody...
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
Biology Products: